Rendering Factor Xa Zymogen-like As a Therapeutic Strategy to Treat Bleeding

Overview

Journal Curr Opin Hematol

Specialty Hematology

Date 2017 Jul 11

PMID 28692575

Citations 3

Authors

Nabil K Thalji

Rodney M Camire

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: New therapies are needed to control bleeding in a range of clinical conditions. This review will discuss the biochemical properties of zymogen-like factor Xa, its preclinical assessment in different model systems, and future development prospects.

Recent Findings: Underlying many procoagulant therapeutic approaches is the rapid generation of thrombin to promote robust clot formation. Clinically tested prohemostatic agents (e.g., factor VIIa) can provide effective hemostasis to mitigate bleeding in hemophilia and other clinical situations. Over the past decade, we explored the possibility of using zymogen-like factor Xa variants to rapidly improve clot formation for the treatment of bleeding conditions. Compared to the wild-type enzyme, these variants adopt an altered, low activity, conformation which enables them to resist plasma protease inhibitors. However, zymogen-like factor Xa variants are conformationally dynamic and ligands such as its cofactor, factor Va, stabilize the molecule rescuing procoagulant activity. At the site of vascular injury, the variants in the presence of factor Va serve as effective prohemostatic agents. Preclinical data support their use to stop bleeding in a variety of clinical settings. Phase 1 studies suggest that zymogen-like factor Xa is safe and well tolerated, and a phase 1b is ongoing to assess safety in patients with intracerebral hemorrhage.

Summary: Zymogen-like factor Xa is a unique prohemostatic agent for the treatment of a range of bleeding conditions.

Citing Articles

Activated factor X delivered by adeno-associated virus significantly inhibited bleeding and alleviated hemophilic synovitis in hemophilic mice.

Zhang F, Zhou X, Hua B, He X, Li Z, Xiao X Gene Ther. 2024; 31(11-12):544-552.

PMID: 39256611 DOI: 10.1038/s41434-024-00479-5.

Adeno-associated virus-mediated expression of activated factor V (FVa) for hemophilia phenotypic correction.

Sun J, Chen X, Chai Z, Niu H, Dobbins A, Nichols T Front Med (Lausanne). 2022; 9:880763.

PMID: 35991645 PMC: 9388760. DOI: 10.3389/fmed.2022.880763.

Directed Evolution Methods for Enzyme Engineering.

Nirantar S Molecules. 2021; 26(18).

PMID: 34577070 PMC: 8470892. DOI: 10.3390/molecules26185599.

References

Mayer S, Davis S, Skolnick B, Brun N, Begtrup K, Broderick J . Can a subset of intracerebral hemorrhage patients benefit from hemostatic therapy with recombinant activated factor VII?. Stroke. 2009; 40(3):833-40. DOI: 10.1161/STROKEAHA.108.524470. View

Mayer S, Brun N, Begtrup K, Broderick J, Davis S, Diringer M . Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2008; 358(20):2127-37. DOI: 10.1056/NEJMoa0707534. View

Khan A, James M . Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci. 1998; 7(4):815-36. PMC: 2143990. DOI: 10.1002/pro.5560070401. View

Hedstrom L, Lin T, Fast W . Hydrophobic interactions control zymogen activation in the trypsin family of serine proteases. Biochemistry. 1996; 35(14):4515-23. DOI: 10.1021/bi951928k. View

Mann K, Nesheim M, Church W, Haley P, Krishnaswamy S . Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood. 1990; 76(1):1-16. View

Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24):2342-52. DOI: 10.1056/NEJMoa0906598. View

Cohen A, Spiro T, Buller H, Haskell L, Hu D, Hull R . Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013; 368(6):513-23. DOI: 10.1056/NEJMoa1111096. View

Mendelow A, Gregson B, Rowan E, Murray G, Gholkar A, Mitchell P . Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet. 2013; 382(9890):397-408. PMC: 3906609. DOI: 10.1016/S0140-6736(13)60986-1. View

Rocino A, Franchini M, Coppola A . Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX. J Clin Med. 2017; 6(4). PMC: 5406778. DOI: 10.3390/jcm6040046. View

10.

Bode W . The transition of bovine trypsinogen to a trypsin-like state upon strong ligand binding. II. The binding of the pancreatic trypsin inhibitor and of isoleucine-valine and of sequentially related peptides to trypsinogen and to.... J Mol Biol. 1979; 127(4):357-74. DOI: 10.1016/0022-2836(79)90227-4. View

11.

Turecek P, Varadi K, Schwarz H . Update on the mechanism of action and future of activated prothrombin complex concentrates. Curr Hematol Rep. 2004; 3(5):331-7. View

12.

Eriksson B, Borris L, Friedman R, Haas S, Huisman M, Kakkar A . Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358(26):2765-75. DOI: 10.1056/NEJMoa0800374. View

13.

Giles A, Mann K, Nesheim M . A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol. 1988; 69(4):491-7. DOI: 10.1111/j.1365-2141.1988.tb02405.x. View

14.

Fredenburgh J, Weitz J . A PoTENtial Antidote: A Prohemostatic Factor Xa Variant for Reversal of Direct Oral Anticoagulants. Circ Res. 2017; 119(11):1157-1160. DOI: 10.1161/CIRCRESAHA.116.309820. View

15.

Anderson C, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C . Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013; 368(25):2355-65. DOI: 10.1056/NEJMoa1214609. View

16.

Turecek P, Gritsch H, Richter G, Auer W, Pichler L, Schwarz H . Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of antibody-induced hemophilia and von Willebrand disease. Thromb Haemost. 1997; 77(3):591-9. View

17.

Lu G, DeGuzman F, Hollenbach S, Karbarz M, Abe K, Lee G . A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013; 19(4):446-51. DOI: 10.1038/nm.3102. View

18.

Escobar M . Health economics in haemophilia: a review from the clinician's perspective. Haemophilia. 2010; 16 Suppl 3:29-34. DOI: 10.1111/j.1365-2516.2010.02257.x. View

19.

Davis S, Broderick J, Hennerici M, Brun N, Diringer M, Mayer S . Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006; 66(8):1175-81. DOI: 10.1212/01.wnl.0000208408.98482.99. View

20.

Lassen M, Ageno W, Borris L, Lieberman J, Rosencher N, Bandel T . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358(26):2776-86. DOI: 10.1056/NEJMoa076016. View